Trial Profile

A phase III trial of CHOP [cyclophosphamide, doxorubicin, vincristine and prednisone] plus rituximab vs CHOP plus iodine-131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 27 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iodine-131 tositumomab (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
Indications Follicular lymphoma; Non-Hodgkin's lymphoma
Focus Therapeutic Use

21 May 2025 Planned End Date changed from 1 Mar 2025 to 1 Dec 2025.
24 Jun 2024 Planned End Date changed from 1 Mar 2024 to 1 Mar 2025.
31 May 2024 According to an Adaptive Biotechnologies media release, results from this trial, to be presented at the European Hematology Association (EHA) Hybrid Congress taking place June 13-16 in Madrid and virtually.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com